At a glance
ClinicalIndex Comparison RecordN/ACompleted· 8,616 enrolled
Drug / intervention
Pantoprazoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pantoprazole for the Treatment of GERD Associated Symptoms Focusing on Sleep Disorders.
In Brief
An observational study evaluating Pantoprazole for Erosive Gastroesophageal Reflux Disease and Non-Erosive Reflux Disease. Completed, enrolled 8,616 participants across 1,153 sites.
Detailed Summary
The aim of the study was to evaluate the effect of Pantoprazole 20 mg/40 mg for 14 days on symptoms in patients with NERD (non-erosive reflux disease) or eGERD (erosive gastroesophageal reflux disease) with special focus on the reduction of symptomatic sleep disorders.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedNov 2007
Primary CompletionApr 2009
TodayJul 2026
First PostedNov 21, 2007
Enrollment StartOct 1, 2007
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 18.6 years ago
Interventions
Pantoprazoledrug
This was an observational study. Therefore, the physician decided about dosage according to individual needs.